British Columbia Centre for Disease Control
15
1
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
6.7%
1 terminated/withdrawn out of 15 trials
85.7%
-0.8% vs industry average
40%
6 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
British Columbia Prescriber Feedback Program - Antimicrobial Resistance
Role: collaborator
Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada
Role: collaborator
Evaluation of an Educational Intervention on Antibiotics in Dental Care
Role: collaborator
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
Role: collaborator
Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex with Men (DaDHS)
Role: lead
TITRE III: Influenza B Immunogenicity Investigation
Role: lead
Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM
Role: lead
Adolescent MenACWY Booster Study
Role: collaborator
Host Response Mediators in Coronavirus (COVID-19) Infection
Role: collaborator
SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack
Role: collaborator
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
Role: collaborator
Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
Role: collaborator
Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity
Role: lead
TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost
Role: lead
TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B
Role: lead
All 15 trials loaded